Cardiometabolic Risk Factors Clinical Trial
Official title:
An Interventional Study for the Beneficial Effects of Probiotics on Cardio-metabolic Health in Chinese Subjects
Verified date | May 2022 |
Source | Sun Yat-sen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of atherosclerosis. Animal studies have demonstrated that administration of probiotics help delay the progression of atherosclerosis through several mechanisms. This trial aims to examine its protective effect in humans.
Status | Completed |
Enrollment | 130 |
Est. completion date | February 28, 2022 |
Est. primary completion date | February 28, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility | Inclusion Criteria: - Local residents aged between 30-60 years old; - Stable weight (<5% weight change over last 3 months); - Central obesity defined as waist circumference =90 cm in males or =80 cm in females, Plus any two of the following four conditions i) Elevated triglycerides: serum triglycerides =150 mg/dL (1.7 mmol/L); ii) Reduced HDL cholesterol: serum HDL-c <40 mg/dL (1.03 mmol/L) in males or <50 mg/dL (1.29 mmol/L) in females; iii) Elevated blood pressure: systolic blood pressure =130 mmHg or diastolic blood pressure =85 mmHg; iv) Elevated fasting plasma glucose: fasting plasma glucose =100 mg/dL (5.6 mmol/L) - Absence of any systemic, cardiovascular diseases, as well as infections within the previous month; - Absence of any diet or medication that might interfere with metabolic homoeostasis and gut microbiota, especially antibiotics and probiotics 4 weeks before recruitment. Exclusion Criteria: - Acute illness or current evidence of acute or chronic inflammatory of infective diseases; - Participation in regular diet program more than 2 times per week in the latest 3 months prior to recruitment; - Mental illness rendering them unable to understand the nature, scope, and possible consequences of the study. |
Country | Name | City | State |
---|---|---|---|
China | Department of Nutrition and Food Hygiene | Guangzhou | Guangdong |
China | Sun Yat-Sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Flow-mediated slowing (FMS) | FMS is a simple test for endothelial functions measured by Vicorder. In patients whose endothelial function or flow-mediated vasodilation are compromised, the FMS is substantially reduced. | from baseline to 12 weeks after intervention | |
Secondary | gut microbiota | Alterations of the composition of gut microbiota evaluated by metagenomics | from baseline to 12 weeks after intervention | |
Secondary | microbial metabolites | alterations of microbial metabolites evaluated by High performance liquid chromatography-mass spectrometry | from baseline to 12 weeks after intervention | |
Secondary | Metabolic Syndrome Severity Z Score (MetZ score) | MetZ score is an weighted score of the five traditional components of Metabolic syndrome (waist, triglyceride, HDL cholesterol, SBP and fasting glucose). It's used to evaluate the severity of metabolic disorder, and a higher score indicates a more severe status. | from baseline to 12 weeks after intervention | |
Secondary | Lipid profiles | alterations of blood lipids including total cholesterol, triglyceride, LDL cholesterol and HDL cholesterol determined by automatic biochemical analyser | from baseline to 12 weeks after intervention | |
Secondary | Blood pressure | alterations of blood pressure | from baseline to 12 weeks after intervention | |
Secondary | Insulin sensitivity | alterations of HOMA-IR index | from baseline to 12 weeks after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04877548 -
Powdered Fermented Fruits for Glycemia Reduction
|
N/A | |
Completed |
NCT05995522 -
Effect of Vitamin K2 Over Osteocalcin, Leptin, Cytokines, and Cardiovascular Risk in Young Adults With Overweight and Obesity
|
N/A | |
Completed |
NCT04021342 -
The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Physiological and Cognitive Function
|
N/A | |
Recruiting |
NCT05777746 -
The Effect of an Online Plant-Based Dietary Program on Cardiovascular Risk Factors in Persons With Type 2 Diabetes Mellitus: A Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT06358859 -
Delta GREENS Food is Medicine Intervention
|
N/A | |
Completed |
NCT06201273 -
Physical Exercise on Physiological Adaptation Capacity and Chronic Pain in Individuals With Cardiovascular Risk
|
N/A | |
Recruiting |
NCT06067009 -
Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi)
|
N/A | |
Recruiting |
NCT05353322 -
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
|
N/A | |
Completed |
NCT03310242 -
Comparison of Sunlight Exposure and Vitamin D Supplementation on Serum 25-hydroxyvitamin D Levels
|
N/A | |
Not yet recruiting |
NCT05403294 -
Impact of New Anthropometric Indices on Outcomes After Cardiac Surgery
|
||
Active, not recruiting |
NCT05071196 -
Facilitated Vegan Diet on Cardiometabolic Endpoints and Trimethylamine N-oxide
|
N/A | |
Completed |
NCT05687240 -
Heart Focused Movement Effects on Cardiometabolic Risk
|
N/A | |
Not yet recruiting |
NCT06159556 -
Effects of Peanuts on Immunity and Cardiometabolic Risk Factors
|
N/A |